Drug Information

Drug General Information
Drug ID
D0S6AQ
Former ID
DIB000800
Drug Name
Ramorelix
Synonyms
Hoe-013
Indication Esophageal cancer [ICD9: 150; ICD10:C15] Discontinued in Phase 1 [546504]
Company
Aventis Pharma AG
Formula
C74H95ClN16O18
Canonical SMILES
N1(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC<br />(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)C)<br />Cc2cc3c(cc2)cccc3)Cc2ccc(Cl)cc2)Cc2c[nH]c3c2cccc3)CO)Cc<br />2ccc(cc2)O)CO[C@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O)O)<br />O)CC(C)C)CCCNC(=N)N)[C@H](C(=O)NNC(=O)N)CCC1
CAS Number
CAS 127932-90-5
PubChem Compound ID
25078113
Target and Pathway
Target(s) Gonadotropin-releasing hormone receptor Target Info Antagonist [534062]
KEGG Pathway Neuroactive ligand-receptor interaction
GnRH signaling pathway
NetPath Pathway IL1 Signaling Pathway
IL2 Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome Hormone ligand-binding receptors
G alpha (q) signalling events
WikiPathways Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 546504Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008630)
Ref 534062Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations. J Cancer Res Clin Oncol. 1993;119(8):457-62.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.